← Oncology Approval Tracker

FDA DECISION ·

Pluvicto

lutetium Lu 177 vipivotide tetraxetan · Novartis

FDA approvalNew or expanded indicationProstate cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with PSMA-positive metastatic castration-resistant prostate cancer after androgen receptor pathway inhibitor therapy who are appropriate candidates to delay taxane chemotherapy.

LAMPGEN ANALYSIS

Why it matters

The decision brought PSMA-targeted radioligand treatment into a pre-taxane setting for eligible patients.

What research teams should watch

Coordinate PSMA imaging, nuclear medicine capacity, radiation handling, and timely referral from oncology.

Related study operations checklist

See the staffing responsibilities, timing, and handoff questions for this study setting.

PSMA-selected radioligand studies

PRIMARY RECORDS

Sources